Heat shock protein 70-2 (HSP70-2) overexpression in breast cancer

Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer. HSP70-2 expression was examined in 154 tumor and 103 adjacent...

Full description

Saved in:
Bibliographic Details
Published inJournal of Experimental & Clinical Cancer Research Vol. 35; no. 1; p. 150
Main Authors Jagadish, Nirmala, Agarwal, Sumit, Gupta, Namita, Fatima, Rukhsar, Devi, Sonika, Kumar, Vikash, Suri, Vaishali, Kumar, Rajive, Suri, Vitusha, Sadasukhi, Trilok Chand, Gupta, Anju, Ansari, Abdul S., Lohiya, Nirmal Kumar, Suri, Anil
Format Journal Article
LanguageEnglish
Published England Springer Science and Business Media LLC 22.09.2016
BioMed Central Ltd
BioMed Central
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer. HSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model. HSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers. HSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment.
AbstractList Background Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer. Methods HSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model. Results HSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers. Conclusions HSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment. Keywords: HSP70-2, Breast cancer, Gene silencing, Apoptosis, Tumor growth
Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer. HSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model. HSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers. HSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment.
BACKGROUNDBreast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer.METHODSHSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model.RESULTSHSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers.CONCLUSIONSHSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment.
Background Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer. Methods HSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model. Results HSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers. Conclusions HSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment.
Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we investigated the potential role and association of HSP70-2 with breast cancer. HSP70-2 expression was examined in 154 tumor and 103 adjacent non-cancerous tissue (ANCT) specimens and breast cancer cell lines (MCF7, BT-474, SK-BR-3 and MDA-MB-231) by RT-PCR, quantitative-PCR, immunohistochemistry, Western blotting, flow cytometry and indirect immunofluorescence. Plasmid driven short hairpin RNA approach was employed to validate the role of HSP70-2 in cellular proliferation, senescence, migration, invasion and tumor growth. Further, we studied the effect of HSP70-2 protein ablation on signaling cascades involved in apoptosis, cell cycle and Epithelial-Mesenchymal-Transition both in culture as well as in-vivo human breast xenograft mouse model. HSP70-2 expression was detected in majority of breast cancer patients (83 %) irrespective of various histotypes, stages and grades. HSP70-2 expression was also observed in all breast cancer cells (BT-474, MCF7, MDA-MB-231 and SK-BR-3) used in this study. Depletion of HSP70-2 in MDA-MB-231 and MCF7 cells resulted in a significant reduction in cellular growth, motility, onset of apoptosis, senescence, cell cycle arrest as well as reduction of tumor growth in the xenograft model. At molecular level, down-regulation of HSP70-2 resulted in reduced expression of cyclins, cyclin dependent kinases, anti-apoptotic molecules and mesenchymal markers and enhanced expression of CDK inhibitors, caspases, pro-apoptotic molecules and epithelial markers. HSP70-2 is over expressed in breast cancer patients and was involved in malignant properties of breast cancer. This suggests HSP70-2 may be potential candidate molecule for development of better breast cancer treatment.
ArticleNumber 150
Audience Academic
Author Sonika Devi
Vitusha Suri
Rajive Kumar
Nirmala Jagadish
Anil Suri
Rukhsar Fatima
Vikash Kumar
T. C. Sadasukhi
Abdul S. Ansari
Nirmal K. Lohiya
Namita Gupta
Sumit Agarwal
Vaishali Suri
Anju Gupta
Author_xml – sequence: 1
  givenname: Nirmala
  surname: Jagadish
  fullname: Jagadish, Nirmala
– sequence: 2
  givenname: Sumit
  surname: Agarwal
  fullname: Agarwal, Sumit
– sequence: 3
  givenname: Namita
  surname: Gupta
  fullname: Gupta, Namita
– sequence: 4
  givenname: Rukhsar
  surname: Fatima
  fullname: Fatima, Rukhsar
– sequence: 5
  givenname: Sonika
  surname: Devi
  fullname: Devi, Sonika
– sequence: 6
  givenname: Vikash
  surname: Kumar
  fullname: Kumar, Vikash
– sequence: 7
  givenname: Vaishali
  surname: Suri
  fullname: Suri, Vaishali
– sequence: 8
  givenname: Rajive
  surname: Kumar
  fullname: Kumar, Rajive
– sequence: 9
  givenname: Vitusha
  surname: Suri
  fullname: Suri, Vitusha
– sequence: 10
  givenname: Trilok Chand
  surname: Sadasukhi
  fullname: Sadasukhi, Trilok Chand
– sequence: 11
  givenname: Anju
  surname: Gupta
  fullname: Gupta, Anju
– sequence: 12
  givenname: Abdul S.
  surname: Ansari
  fullname: Ansari, Abdul S.
– sequence: 13
  givenname: Nirmal Kumar
  surname: Lohiya
  fullname: Lohiya, Nirmal Kumar
– sequence: 14
  givenname: Anil
  surname: Suri
  fullname: Suri, Anil
BackLink https://cir.nii.ac.jp/crid/1873116918034205568$$DView record in CiNii
https://www.ncbi.nlm.nih.gov/pubmed/27658496$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1rFDEUhgep2A_9Ad7IgFLqxdSczOTrRliKukJBQb0OmcyZbupssk1miv77ZthWd4tIyAfJ875JzjnHxYEPHoviJZBzAMnfJahJwysCuTeUVepJcQSC8Uopzg921ofFcUrXhHBQoJ4Vh1RwJhvFj4rFEs1YplWwP8tNDCM6XwpS0fJs-e3rvHhbhluM-GsTMSUXfJmBNqJJY2mNtxifF097MyR8cT-fFD8-fvh-sawuv3z6fLG4rCynZKyw7jrLOlubnnactAQlBYCuFSKfGKu4Ia3oG-xaQE6kANI0CmtjGSAIW58U77e-m6ldY2fRj9EMehPd2sTfOhin90-8W-mrcKsZqZuGi2xwdm8Qw82EadRrlywOg_EYpqRBMiWo5JRn9PUj9DpM0efvZYoyKbli6i91ZQbUzvch32tnU71oBGFSCVln6vwfVG4drp3NCe1d3t8TnO4IVmiGcZXCMI05-mkffLUbkT-heMhuBsQWsDGkFLHX1o1m9slPcIMGouc60ts60rmO9FxHev4aPFI-mP9P82ar8c7li-YRpKgBuAKZc0AJY1zWd7Jd0CU
CitedBy_id crossref_primary_10_1186_s13048_018_0475_z
crossref_primary_10_1002_mco2_161
crossref_primary_10_1016_j_prp_2022_154127
crossref_primary_10_1139_bcb_2018_0177
crossref_primary_10_1177_1533033818785274
crossref_primary_10_3390_cancers12102749
crossref_primary_10_3390_cells10123446
crossref_primary_10_1038_s41598_019_43556_1
crossref_primary_10_17826_cumj_435450
crossref_primary_10_3390_ijms19092603
crossref_primary_10_3390_cells9102332
crossref_primary_10_3390_ijms24087485
crossref_primary_10_3390_ijms21124296
crossref_primary_10_1002_mco2_70129
crossref_primary_10_2217_epi_2023_0154
crossref_primary_10_1007_s00216_019_02220_3
crossref_primary_10_1038_s41418_019_0400_z
crossref_primary_10_1038_s41388_019_0978_0
crossref_primary_10_3390_cancers13061252
crossref_primary_10_1002_cbdv_202200746
crossref_primary_10_1371_journal_pone_0200619
crossref_primary_10_1007_s00383_017_4211_3
crossref_primary_10_1155_2022_6229444
crossref_primary_10_1016_j_tranon_2020_100754
crossref_primary_10_1016_j_tranon_2020_100776
crossref_primary_10_1021_acs_molpharmaceut_4c00140
crossref_primary_10_1590_1806_9282_20210495
crossref_primary_10_1016_j_identj_2024_10_008
crossref_primary_10_1158_2767_9764_CRC_24_0094
crossref_primary_10_2174_1389450120666181211111815
crossref_primary_10_3390_ijms23147792
crossref_primary_10_1186_s12885_021_08041_x
crossref_primary_10_3389_fonc_2021_749673
crossref_primary_10_3390_cancers14030605
crossref_primary_10_3390_app11031175
crossref_primary_10_1016_j_molmed_2019_05_011
crossref_primary_10_1021_acsnano_8b03726
crossref_primary_10_3390_cells9010060
crossref_primary_10_1134_S1990519X23010066
crossref_primary_10_3390_molecules27207132
crossref_primary_10_3390_ijms25020876
crossref_primary_10_1002_1878_0261_12821
crossref_primary_10_52711_0974_360X_2022_00273
crossref_primary_10_1016_j_clbc_2020_11_005
crossref_primary_10_1016_j_ejcb_2017_09_003
crossref_primary_10_3390_cancers14174289
Cites_doi 10.1007/s13277-014-2594-5
10.1016/j.bbrc.2008.03.040
10.1002/cncr.25218
10.2174/1381612821666141211154707
10.1038/cddis.2014.244
10.1101/gad.305405
10.2217/bmt.12.60
10.1016/j.ejca.2009.10.020
10.1242/dev.124.15.3007
10.3322/caac.21332
10.1371/journal.pone.0057095
10.1186/s13046-015-0258-y
10.1111/j.1524-4741.2007.00393.x
10.1038/nrm1835
10.1111/j.1582-4934.2009.00873.x
10.1158/1055-9965.EPI-08-0629
10.1073/pnas.1017909109
10.1158/2159-8290.CD-12-0429
10.1016/j.arcmed.2013.10.005
10.1038/nature13119
10.1016/S0140-6736(13)62224-2
10.1186/bcr3168
10.1002/path.3022
10.1016/j.tibs.2006.01.006
10.4137/CPath.S31563
10.1371/journal.pone.0081348
10.1016/j.cell.2011.02.013
ContentType Journal Article
Copyright COPYRIGHT 2016 BioMed Central Ltd.
Copyright BioMed Central 2016
The Author(s). 2016
Copyright_xml – notice: COPYRIGHT 2016 BioMed Central Ltd.
– notice: Copyright BioMed Central 2016
– notice: The Author(s). 2016
DBID RYH
AAYXX
CITATION
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1186/s13046-016-0425-9
DatabaseName CiNii Complete
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
Publicly Available Content Database
PubMed

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-9966
EndPage 150
ExternalDocumentID PMC5034467
4203985351
A470589783
27658496
10_1186_s13046_016_0425_9
Genre Journal Article
GeographicLocations India
GeographicLocations_xml – name: India
GrantInformation_xml – fundername: ;
– fundername: ;
  grantid: BT/IN/UK/NII/2006; BT/PR/14549/MED/14/1291
GroupedDBID ---
0R~
29K
2WC
4.4
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFO
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
H13
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
RYH
SMD
SOJ
TR2
TUS
UKHRP
~8M
AAYXX
CITATION
NPM
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c620t-e3ddc5dc3af2d60b0e82111db773ddac96a0b7f4edb1e608710449e3ac51e17c3
IEDL.DBID M48
ISSN 1756-9966
0392-9078
IngestDate Thu Aug 21 13:50:40 EDT 2025
Fri Jul 11 09:19:34 EDT 2025
Fri Jul 25 05:14:27 EDT 2025
Tue Jun 17 22:05:15 EDT 2025
Tue Jun 10 21:05:01 EDT 2025
Thu May 22 21:24:16 EDT 2025
Thu Apr 03 07:08:45 EDT 2025
Tue Jul 01 02:26:28 EDT 2025
Thu Apr 24 23:01:26 EDT 2025
Thu Jun 26 23:05:41 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords HSP70-2
Gene silencing
Breast cancer
Tumor growth
Apoptosis
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c620t-e3ddc5dc3af2d60b0e82111db773ddac96a0b7f4edb1e608710449e3ac51e17c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-5244-5069
0000-0002-5812-9283
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13046-016-0425-9
PMID 27658496
PQID 1825886959
PQPubID 105475
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5034467
proquest_miscellaneous_1859728626
proquest_journals_1825886959
gale_infotracmisc_A470589783
gale_infotracacademiconefile_A470589783
gale_healthsolutions_A470589783
pubmed_primary_27658496
crossref_citationtrail_10_1186_s13046_016_0425_9
crossref_primary_10_1186_s13046_016_0425_9
nii_cinii_1873116918034205568
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-09-22
PublicationDateYYYYMMDD 2016-09-22
PublicationDate_xml – month: 09
  year: 2016
  text: 2016-09-22
  day: 22
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of Experimental & Clinical Cancer Research
PublicationTitleAlternate J Exp Clin Cancer Res
PublicationYear 2016
Publisher Springer Science and Business Media LLC
BioMed Central Ltd
BioMed Central
Publisher_xml – name: Springer Science and Business Media LLC
– name: BioMed Central Ltd
– name: BioMed Central
References O Straume (425_CR6) 2012; 109
B Shang (425_CR26) 2014; 5
CJ Dougherty (425_CR21) 2008; 370
Q Cheng (425_CR7) 2012; 14
P Yang (425_CR25) 2015; 21
J Tabernero (425_CR27) 2013; 3
M Garg (425_CR9) 2010; 46
GJ Lindeman (425_CR20) 2013; 2
P Vineis (425_CR4) 2014; 383
J Makki (425_CR2) 2015; 8
N Jagadish (425_CR14) 2015; 34
GH Williams (425_CR18) 2012; 226
M Rohde (425_CR8) 2005; 19
J Wang (425_CR23) 2009; 13
D Kanojia (425_CR13) 2013; 8
S Singh (425_CR11) 2014; 35
JP Thiery (425_CR24) 2006; 7
D Zhu (425_CR19) 1997; 124
X Chen (425_CR22) 2014; 508
D Hanahan (425_CR17) 2011; 144
S Saini (425_CR15) 2013; 8
D Kanojia (425_CR12) 2009; 18
SY Hou (425_CR16) 2014; 45
SK Calderwood (425_CR5) 2006; 31
R Siegel (425_CR1) 2016; 66
BJ Yoder (425_CR3) 2007; 13
M Garg (425_CR10) 2010; 116
25506890 - Curr Pharm Des. 2015;21(10):1292-300
26740749 - Clin Med Insights Pathol. 2015 Dec 21;8:23-31
24316396 - Arch Med Res. 2014 Jan;45(1):44-51
23358650 - Cancer Discov. 2013 Apr;3(4):406-17
26590805 - J Exp Clin Cancer Res. 2015 Nov 21;34:142
16493418 - Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42
24351322 - Lancet. 2014 Feb 8;383(9916):549-57
24349057 - PLoS One. 2013 Dec 09;8(12):e81348
21376230 - Cell. 2011 Mar 4;144(5):646-74
19190149 - Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):630-9
16483782 - Trends Biochem Sci. 2006 Mar;31(3):164-72
21990031 - J Pathol. 2012 Jan;226(2):352-64
24670641 - Nature. 2014 Apr 3;508(7494):103-7
15741319 - Genes Dev. 2005 Mar 1;19(5):570-82
9247342 - Development. 1997 Aug;124(15):3007-14
26742998 - CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
20564126 - Cancer. 2010 Aug 15;116(16):3785-96
19914824 - Eur J Cancer. 2010 Jan;46(1):207-15
24901056 - Cell Death Dis. 2014 Jun 05;5:e1285
19674193 - J Cell Mol Med. 2009 Sep;13(9B):3888-97
18355444 - Biochem Biophys Res Commun. 2008 May 23;370(1):109-12
23451156 - PLoS One. 2013;8(2):e57095
22589302 - Proc Natl Acad Sci U S A. 2012 May 29;109(22):8699-704
25213699 - Tumour Biol. 2014 Dec;35(12):12695-706
22510516 - Breast Cancer Res. 2012 Apr 17;14(2):R62
17319859 - Breast J. 2007 Mar-Apr;13(2):172-9
References_xml – volume: 35
  start-page: 12695
  year: 2014
  ident: 425_CR11
  publication-title: Tumor Biol
  doi: 10.1007/s13277-014-2594-5
– volume: 370
  start-page: 109
  year: 2008
  ident: 425_CR21
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2008.03.040
– volume: 116
  start-page: 3785
  year: 2010
  ident: 425_CR10
  publication-title: Cancer
  doi: 10.1002/cncr.25218
– volume: 21
  start-page: 1292
  year: 2015
  ident: 425_CR25
  publication-title: Curr Pharm Des
  doi: 10.2174/1381612821666141211154707
– volume: 5
  start-page: e1285
  year: 2014
  ident: 425_CR26
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2014.244
– volume: 19
  start-page: 570
  year: 2005
  ident: 425_CR8
  publication-title: Genes Dev
  doi: 10.1101/gad.305405
– volume: 2
  start-page: 1
  year: 2013
  ident: 425_CR20
  publication-title: Breast Cancer Manag
  doi: 10.2217/bmt.12.60
– volume: 46
  start-page: 207
  year: 2010
  ident: 425_CR9
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2009.10.020
– volume: 124
  start-page: 3007
  year: 1997
  ident: 425_CR19
  publication-title: Development
  doi: 10.1242/dev.124.15.3007
– volume: 66
  start-page: 7
  year: 2016
  ident: 425_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21332
– volume: 8
  start-page: e57095
  year: 2013
  ident: 425_CR15
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0057095
– volume: 34
  start-page: 142
  year: 2015
  ident: 425_CR14
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-015-0258-y
– volume: 13
  start-page: 172
  year: 2007
  ident: 425_CR3
  publication-title: Breast J
  doi: 10.1111/j.1524-4741.2007.00393.x
– volume: 7
  start-page: 131
  year: 2006
  ident: 425_CR24
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm1835
– volume: 13
  start-page: 3888
  year: 2009
  ident: 425_CR23
  publication-title: J Cell Mol Med
  doi: 10.1111/j.1582-4934.2009.00873.x
– volume: 18
  start-page: 630
  year: 2009
  ident: 425_CR12
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-08-0629
– volume: 109
  start-page: 8699
  year: 2012
  ident: 425_CR6
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1017909109
– volume: 3
  start-page: 406
  year: 2013
  ident: 425_CR27
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-12-0429
– volume: 45
  start-page: 44
  year: 2014
  ident: 425_CR16
  publication-title: Arch Med Res
  doi: 10.1016/j.arcmed.2013.10.005
– volume: 508
  start-page: 103
  year: 2014
  ident: 425_CR22
  publication-title: Nature
  doi: 10.1038/nature13119
– volume: 383
  start-page: 549
  year: 2014
  ident: 425_CR4
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)62224-2
– volume: 14
  start-page: R62
  year: 2012
  ident: 425_CR7
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3168
– volume: 226
  start-page: 352
  year: 2012
  ident: 425_CR18
  publication-title: J Pathol
  doi: 10.1002/path.3022
– volume: 31
  start-page: 164
  year: 2006
  ident: 425_CR5
  publication-title: Trends Biochem Sci
  doi: 10.1016/j.tibs.2006.01.006
– volume: 8
  start-page: 23
  year: 2015
  ident: 425_CR2
  publication-title: Clin Med Insights Pathol
  doi: 10.4137/CPath.S31563
– volume: 8
  start-page: e81348
  year: 2013
  ident: 425_CR13
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0081348
– volume: 144
  start-page: 646
  year: 2011
  ident: 425_CR17
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– reference: 26590805 - J Exp Clin Cancer Res. 2015 Nov 21;34:142
– reference: 25506890 - Curr Pharm Des. 2015;21(10):1292-300
– reference: 23451156 - PLoS One. 2013;8(2):e57095
– reference: 16493418 - Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42
– reference: 21990031 - J Pathol. 2012 Jan;226(2):352-64
– reference: 15741319 - Genes Dev. 2005 Mar 1;19(5):570-82
– reference: 26740749 - Clin Med Insights Pathol. 2015 Dec 21;8:23-31
– reference: 26742998 - CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
– reference: 21376230 - Cell. 2011 Mar 4;144(5):646-74
– reference: 24351322 - Lancet. 2014 Feb 8;383(9916):549-57
– reference: 19914824 - Eur J Cancer. 2010 Jan;46(1):207-15
– reference: 24901056 - Cell Death Dis. 2014 Jun 05;5:e1285
– reference: 19674193 - J Cell Mol Med. 2009 Sep;13(9B):3888-97
– reference: 24316396 - Arch Med Res. 2014 Jan;45(1):44-51
– reference: 16483782 - Trends Biochem Sci. 2006 Mar;31(3):164-72
– reference: 20564126 - Cancer. 2010 Aug 15;116(16):3785-96
– reference: 18355444 - Biochem Biophys Res Commun. 2008 May 23;370(1):109-12
– reference: 22510516 - Breast Cancer Res. 2012 Apr 17;14(2):R62
– reference: 23358650 - Cancer Discov. 2013 Apr;3(4):406-17
– reference: 25213699 - Tumour Biol. 2014 Dec;35(12):12695-706
– reference: 24349057 - PLoS One. 2013 Dec 09;8(12):e81348
– reference: 24670641 - Nature. 2014 Apr 3;508(7494):103-7
– reference: 22589302 - Proc Natl Acad Sci U S A. 2012 May 29;109(22):8699-704
– reference: 17319859 - Breast J. 2007 Mar-Apr;13(2):172-9
– reference: 9247342 - Development. 1997 Aug;124(15):3007-14
– reference: 19190149 - Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):630-9
SSID ssj0061919
ssib005900188
Score 2.3817313
Snippet Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present study, we...
Background Breast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present...
BACKGROUNDBreast cancer is one of the leading cause of cancer-related deaths in women worldwide and increasing rapidly in developing countries. In the present...
SourceID pubmedcentral
proquest
gale
pubmed
crossref
nii
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 150
SubjectTerms Analysis
Breast cancer
Development and progression
Gene expression
Genetic aspects
Heat shock proteins
Influence
Stem cell research
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ra9wwDDdrB2Nfxt67rt08GOwBprHj-PFpHGPlGHQMtsJ9M_Ej9KDkut4V9udXcnzZMkY_JASkJI4tyZKt_ETIW2vAK066ZbVKDZNRgkpF61mUUscQG97lcm-n39TiTH5dNsuy4LYpaZU7m5gNdVwHXCM_Bj-4MUbZxn66_MWwahTurpYSGnvkLkKXYUqXXo4BF8QGubAHzJCKoV9fdjW5UccbjluCEEjDAWLL7GReKtZ5r1-t_ud5_ptA-deMdPKQPCiuJJ0PY_-I3En9Y3LvtGyWPyHzBdhZujkHi0czHMOqp7pigr5f_PiOFx8o5m-m3yUXtqfA4DFJfUsDCsPVU3J28uXn5wUrFRNYUKLaslTHGJoY6rYTUVW-SgYCPB691kBpg1Vt5XUnU_Q8qQqCpUpKm-o2NDxxHepnZL9f9-kFoV75ZE2dOiutVJ1ovQwyiIh1IVqv6xmpdv3lQoETx6oWFy6HFUa5oYsdppBhFzs7Ix_HWy4HLI3bmF_jILjhd9BRD91caqyEqA204F3mQE2EN4e2_FAA7UdMqwnn4YQTNChMyEcw0PAVeOZG1xwRhAyCIyLUkIHbdyLgioZv3B95nJE3IxmfjFlrfVpfIw-EawJjxhl5PkjM-OFCo-9ngaInsjQyIO73lNKvzjP-d4MwjUof3N6sl-S-yOJtmRCHZH97dZ2OwIHa-ldZS24ACycR8w
  priority: 102
  providerName: ProQuest
Title Heat shock protein 70-2 (HSP70-2) overexpression in breast cancer
URI https://cir.nii.ac.jp/crid/1873116918034205568
https://www.ncbi.nlm.nih.gov/pubmed/27658496
https://www.proquest.com/docview/1825886959
https://www.proquest.com/docview/1859728626
https://pubmed.ncbi.nlm.nih.gov/PMC5034467
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swEBdNC2MvY9_N1mYeDAYDbbIs6-NhjHa0hEHKKAuEvRjrwzRQ3C1JofvvdycrZh5h7MF68J1t6Xwn3Vnn3xHyxmjwioOqaSFDSYUXYFLeWOqFUN75Mm9iubfZhZzOxZdFudgj2_JWSYDrnaEd1pOar67f3_389QkM_mM0eC0_rHPc3oOgGA5QQWpG5AAWJoV2OhP9pgKECrHOBwOXgEJMqNMm585bDJapNFmP2uVylyP6dz7lHwvU-UPyIHmW2UmnCo_IXmgfk3uztHf-hKgpTLvZ-gomwCyiMyzbTDHKM0ziDHcpIbbN4LTFTPVN5lAjVk_J_Pzs2-cpTWUTqJOcbWgovHeld0XdcC-ZZUFDlJd7qxRQamdkzaxqRPA2D5JBxMSEMKGoXZmHXLniGdlvb9pwSDIrbTC6CI0RRsiG11Y44bjH4hC1VcWYsK2UKpcwxbG0xXUVYwstq06wFeaRoWArMybv-kt-dIAa_2J-haKvun9Ce2OsToTCcohKQw_eRg5UEHiyq9NfBdB_BLYacB4NOMGM3IB8DK8XRoFtrlWRI4yQRoRExBvScPn2xVdbLQU-XmotTQk9fd2T8c6YutaGm1vkgZiNY-A4Js87PekHzhU6gAYoaqBBPQOCfw8p7fIqgoCXiNUo1Yv_Hv9Lcp9H_TaU8yOyv1ndhmNwqDZ2QkZqoSbk4PTs4uvlJH6WmETTgfby9PtvspgbOQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELbarQR9QdwstDRIIA7JauI4Ph4QWqDVlnZXFbRS30x8RF2pypbuVsCf4jcykwuCUN_6sKuVPEkce2Y833r8DSHPtYKoOMicpiJklHsOJuW1pZ5z6Z3PkqIq9zaZivEx_3SSnayQX-1ZGEyrbH1i5aj93OF_5NsQB2dKCZ3pd-ffKFaNwt3VtoRGrRb74ed3gGyLt3sfYX5fMLa7c_RhTJuqAtQJFi9pSL13mXdpXjAvYhsHBSAo8VZKaMmdFnlsZcGDt0kQMQCKmHMd0txlSUikS-G-q2SNpwBlBmTt_c708HPr-wGNVKVEYE0WFJFEs4-aKLG9SHATEqA7fMBQqO6thM16sFrOZv-Ldf9N2fxrDdy9TW41wWs0qrXtDlkJ5V1yY9Jsz98jozF49mhxCj42qgggZmUkY8qiV-Mvh_jjdYQZo-FHk31bRiBgMS1-GTlUv4v75PhaRvMBGZTzMjwikRU2aJWGQnPNRcFyyx13zGMlitzKdEjidryMawjMsY7GmamAjBKmHmKDSWs4xEYPyZvukvOaveMq4S2cBFMfQO0s34y4xNqLUkEPXlYSaPvwZJc3Rxig_8ii1ZPc6EmCzbpe8yZMNLwFfidKpglyFimkY0RyIwWXtypgGp-yMH8sYEiedc14Z8yTK8P8EmUAIDJEqUPysNaY7sWZxGhTQ4vs6VIngEzj_ZZydloxjmdIDCnk46u7tUVujo8mB-Zgb7r_hKyzStU1ZWyDDJYXl2ETwrelfdrYTES-XreZ_gYCllGY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Heat+shock+protein+70-2+overexpression+in+breast+cancer&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Jagadish%2C+Nirmala&rft.au=Agarwal%2C+Sumit&rft.au=Gupta%2C+Namita&rft.au=Fatima%2C+Rukhsar&rft.date=2016-09-22&rft.pub=BioMed+Central+Ltd&rft.issn=0392-9078&rft.volume=35&rft.issue=1&rft_id=info:doi/10.1186%2Fs13046-016-0425-9&rft.externalDocID=A470589783
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon